Kura Oncology (NASDAQ:KURA) Trading Up 6.7% – Here’s What Happened

Kura Oncology, Inc. (NASDAQ:KURA)’s stock price traded up 6.7% during mid-day trading on Monday . The stock traded as high as $8.40 and last traded at $8.44. 1,697,523 shares changed hands during trading, an increase of 14% from the average session volume of 1,487,299 shares. The stock had previously closed at $7.91.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on KURA. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Tuesday, November 19th. TD Cowen restated a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. Scotiabank lowered their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. UBS Group began coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 target price on the stock. Finally, StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $27.38.

Kura Oncology Price Performance

The company has a 50 day moving average of $8.83 and a 200-day moving average of $15.16. The firm has a market capitalization of $703.73 million, a P/E ratio of -3.83 and a beta of 0.78. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same quarter last year, the company earned ($0.50) EPS. On average, sell-side analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Insider Transactions at Kura Oncology

In other news, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. This represents a 5.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 12,255 shares of company stock valued at $100,739 in the last 90 days. 5.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. nVerses Capital LLC bought a new position in Kura Oncology during the 3rd quarter valued at approximately $25,000. China Universal Asset Management Co. Ltd. grew its position in shares of Kura Oncology by 11.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock valued at $144,000 after acquiring an additional 1,750 shares during the period. Point72 DIFC Ltd purchased a new position in Kura Oncology during the third quarter valued at approximately $146,000. US Bancorp DE increased its stake in Kura Oncology by 184.5% in the 4th quarter. US Bancorp DE now owns 22,104 shares of the company’s stock worth $193,000 after buying an additional 14,335 shares in the last quarter. Finally, Erste Asset Management GmbH bought a new stake in Kura Oncology during the 3rd quarter valued at approximately $215,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.